You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》花旗降再鼎醫藥(ZLAB.US)目標價至66美元 評級「買入」
阿思達克 06-11 12:32
花旗發表研究報告,將再鼎醫藥(09688.HK)(ZLAB.US)目標價從71美元下調至66美元,並相應調整了每股盈測,因採用再鼎醫藥2024年年末股數而非之前的2024年加權平均股數。今年下半年再鼎醫藥受到旗下藥物Vyvgart、Xacduro、Augtyro和Nuzyra加速增長的支撐,花旗將其收入預測略微調整至指引的高端。花旗的預測與再鼎醫藥管理層先前溝通的目標一致,即在2025年第四季度實現非GAAP盈利。 該行對再鼎醫藥評級爲「買入/高風險」。該行相信再鼎醫藥的商業策略通過引進外國藥物並在中國市場推進上市,能創造顯着價值,其內部開發的產品管線也逐漸成爲投資論點的重要驅動力(例如DLL3)。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account